Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   Amyris

Amerikaanse aandelen« Terug naar discussie overzicht

Amyris

Volgen
244 Posts
Pagina: «« 1 2 3 4 5 6 ... 13 »» | Laatste | Omlaag ↓
  3. nobahamas 18 oktober 2016 23:03
    Ik hoop dat je een grapje maakt Veer, maar ik begrijp de strekking van je boodschap.
    Ik heb nooit gegokt op één paard, en hoop dat anderen dat ook niet doen.
    Accepteer je winst in dit aandeel, en probeer op tijd te cashen.
    Het tijdstip van kopen en verkopen zijn cruciaal in het behalen van de hoogte van het rendement van beleggen. :)
  16. [verwijderd] 30 oktober 2016 15:07
    De komende week mogen we zeker weer wat verwachten van Amyris. Want even na kwart over 2 in California (dus na sluitingstijd Wall Street) deed Amyris een persbericht met de volgende titel de deur uitgaan:

    Amyris Enters Collaboration with Top 10 Pharmaceutical Company for Biosynthetic Drug Discovery

    Het volledige bericht (waarvan we maandag toch wederom een positieve reactie op de beurs mogen verwachten):

    EMERYVILLE, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, is pleased to announce it has entered into a research agreement with a commercial license option with one of the top 10 largest global pharmaceutical companies. Under the terms of the agreement, the collaboration will use Amyris's µPharmTM platform technology to develop a customized library of natural and natural-like compounds to test its partner’s target antibiotic therapeutic.

    Nature has been a great source for therapeutics, ranging from antibiotics to statins that lower cholesterol levels; however, Nature's potential is often under-utilized due to scarcity or unavailability. Amyris's µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. It not only provides access to scarce natural compounds, but also creates new diversity based on natural compound scaffolds.

    “We’re pleased to have executed our second large µPharm collaboration during the second half of 2016 as planned,” said John Melo, Amyris President and CEO. “We are continuing to experience significant momentum in our business and within biopharma alone we have now executed agreements with three of the top companies in the industry, each leaders in their fields.”

    "Adding another top pharmaceutical company partner to our collaboration portfolio demonstrates the robust growth opportunity we see in the space," said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations. "The flexibility and power of Amyris’s technology platform can be harnessed for a variety of applications and within biopharma can open a new area of compounds that have never been accessible for new drug discovery."

    Amyris will utilize the µPharm platform technology to develop a library of natural and natural-like compounds and test the efficacy of those compounds in vivo for hits against the identified target. This is a different approach than traditional high throughput screening, which typically applies thousands of chemical compounds in in vitro screens to find a drug candidate. Instead, the µPharm platform starts with the target to improve efficiency, identifies candidate natural compound structures, and then creates diversity around those structures for in vivo testing.
  17. [verwijderd] 31 oktober 2016 18:05
    Wederom positief nieuws van Amyris (koers heeft even geen zin verder omhoog te gaan, maar goed, dat komt wel weer):

    BIOSSANCE™ to Launch in Sephora Stores
    Mon October 31, 2016 8:30 AM|GlobeNewswire|About: AMRS
    GlobeNewswire
    EMERYVILLE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Biossance™, the consumer beauty brand from Amyris, Inc. (AMRS), today announced its planned launch in Sephora’s retail stores where the brand’s expansive line of high-performance skin care products will be available to consumers. The rollout to initial participating stores will begin in February 2017 and coincide with launching on Sephora online. Additional in-store and online marketing activities with Sephora to highlight the Biossance brand shortly following launch are planned.

    “We are excited to launch with Sephora in the coming months and look forward to a strong partnership with them in the years to come. We expect this partnership combined with our strong growth will more than double our revenue in 2017,” said Caroline Hadfield, Senior Vice President, Personal Care, at Amyris. “Amyris and Sephora share similar philosophies when it comes to innovation, sustainability, and responsibility while providing efficacious products and we are delighted by their support of our brand.”

    Sephora is the leading specialty beauty retailer globally, teaching and inspiring clients to play in a world of beauty. Sephora has earned its reputation with its expertise, innovation, and entrepreneurial spirit, and has been changing the face of prestige cosmetics since its debut in Paris in the early 1970’s. Now with more than 2,300 stores in 33 countries - including more than 500 stores across North America - plus an award-winning website and an intuitive mobile app, clients have the opportunity to discover 14,000 products from 200 carefully curated brands anytime, anywhere, anyhow.

    About Biossance
    Biossance uses innovative biotechnology to create skincare products that are incredibly effective, sustainable and safe. In its Berkeley-born labs 100% plant-based squalane was created sustainably from sugarcane. Biossance formulates with a No Compromise™ approach, proudly blacklisting over 2,000 ingredients that are potentially harmful to you or the planet. Pioneering sustainable beauty through biotechnology, Biossance makes sure only the most trustworthy and powerful ingredients make the final cut. The full Biossance skin care and beauty collection can be found at www.Biossance.com.

    About Amyris
    Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals.
  19. [verwijderd] 31 oktober 2016 21:19
    Amyris to Present at Benchmark Micro Cap Discovery One-on-One Conference December 1, 2016
    Mon October 31, 2016 3:42 PM|GlobeNewswire|About: AMRS
    EMERYVILLE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that management will be presenting at the Benchmark Company, LLC Micro Cap Discovery One-on-One Conference to be held December 1, 2016, at the Palmer House Hilton Hotel in Chicago. Due to the format of the event, no webcast will be available.

    Management will be available for one-on-one meetings with institutional investors throughout the conference. Interested investors should contact their Benchmark Company, LLC, representative to schedule a meeting.

    Amyris is scheduling an investor day in New York to provide a detailed update regarding recently announced collaborations and to provide an update to the progress on its forward outlook.
244 Posts
Pagina: «« 1 2 3 4 5 6 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
THEON INTERNAT 11,920 +0,86 +7,78%
Pharming 0,839 +0,04 +4,87%
NX FILTRATION 3,160 +0,14 +4,64%
B&S Group SA 4,390 +0,15 +3,66%
Flow Traders 22,440 +0,26 +1,17%
PROSUS 39,975 +0,05 +0,14%
CM.COM 5,400 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 1,038 -0,03 -2,94%
ASML 696,500 -20,80 -2,90%
BESI 127,800 -3,75 -2,85%
ASMI 560,600 -16,40 -2,84%
TomTom 5,420 -0,15 -2,61%
Sligro 10,700 -0,28 -2,55%
TKH 31,000 -0,80 -2,52%
ADYEN NV 1.466,200 -37,20 -2,47%
CTP 14,900 -0,34 -2,23%
SIGNIFY NV 20,840 -0,46 -2,16%
IMCD 141,650 -2,95 -2,04%
Aperam 25,080 -0,52 -2,03%
AMG Critical Materials N.V. 13,540 -0,28 -2,03%
Alfen N.V. 11,515 -0,23 -2,00%
AALBERTS NV 34,320 -0,70 -2,00%
WDP 18,840 -0,38 -1,98%
Fugro 16,350 -0,30 -1,80%
AZERION 1,002 -0,02 -1,76%
RANDSTAD NV 39,580 -0,66 -1,64%
Aegon 5,536 -0,09 -1,63%
Basic-Fit 20,600 -0,34 -1,62%
Galapagos 25,300 -0,40 -1,56%
UMG 24,550 -0,38 -1,52%
Sif Holding 11,680 -0,16 -1,35%
ASR Nederland 44,070 -0,59 -1,32%
BAM 4,340 -0,06 -1,27%
Van Lanschot Kempen NV 42,950 -0,55 -1,26%
HEIJMANS KON 31,650 -0,40 -1,25%
Vastned 20,700 -0,25 -1,19%
Akzo Nobel 55,460 -0,66 -1,18%
FASTNED 21,300 -0,25 -1,16%
Avantium 1,734 -0,02 -1,14%
JUST EAT TAKEAWAY 13,985 -0,16 -1,13%
DSM FIRMENICH AG 97,900 -1,12 -1,13%
EXOR NV 88,900 -1,00 -1,11%
Fagron 18,180 -0,20 -1,09%
Arcadis 60,000 -0,65 -1,07%
Heineken 68,820 -0,74 -1,06%
Vopak 41,740 -0,44 -1,04%
ABN AMRO BANK N.V. 14,495 -0,15 -1,02%
Kendrion 10,100 -0,10 -0,98%
Wolters Kluwer 162,200 -1,55 -0,95%
OCI 10,610 -0,10 -0,93%
NN Group 41,380 -0,39 -0,93%
RENEWI 9,560 -0,09 -0,93%
Eurocommercial Properties 22,200 -0,20 -0,89%
ArcelorMittal 22,650 -0,20 -0,88%
Philips Koninklijke 23,980 -0,21 -0,87%
ALLFUNDS GROUP 5,195 -0,04 -0,86%
AMX 836,55 -7,10 -0,84%
AEX 885,32 -7,34 -0,82%
Brunel 8,660 -0,07 -0,80%
RELX 44,840 -0,34 -0,75%
INPOST 16,160 -0,12 -0,74%
Nedap N.V. 54,000 -0,40 -0,74%
Wereldhave 13,540 -0,10 -0,73%
ForFarmers 3,390 -0,02 -0,73%
NSI 19,000 -0,14 -0,73%
JDE PEET'S 16,750 -0,11 -0,65%
ING 14,730 -0,10 -0,65%
Air France-KLM 8,376 -0,05 -0,64%
PostNL 1,011 -0,01 -0,59%
Corbion 21,420 -0,08 -0,37%
ASCX 1.242,56 -4,52 -0,36%
Accsys 0,557 0,00 -0,36%
SHELL PLC 29,500 -0,07 -0,25%
UNILEVER PLC 55,740 -0,14 -0,25%
KPN 3,560 -0,01 -0,20%
SBM Offshore 16,600 -0,02 -0,12%
ACOMO 17,240 -0,02 -0,12%
Ahold Delhaize 31,610 -0,03 -0,09%
vlag naam koers verschil relatief verschil
AEX 885,37 -7,29 -0,82%
AEX GR 3.466,17 -35,12 -1,00%
Germany40^ 20.087,10 -155,47 -0,77%
FTSE 100 8.105,77 -93,34 -1,14%
EURO50 4.904,91 +15,50 +0,32%
US30^ 42.479,20 +183,40 +0,43%
Nasd100^ 21.289,20 +82,00 +0,39%
US500^ 5.892,28 +21,22 +0,36%
Japan225^ 39.312,80 +839,70 +2,18%
VD-NEW 13,50 -0,19 -1,40%
#/^ Index indications calculated real time, zie disclaimer